Cancer TARGETases: DSB repair as a pharmacological target

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F16%3A00064995" target="_blank" >RIV/00159816:_____/16:00064995 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/16:00087848

Result on the web

<a href="http://dx.doi.org/10.1016/j.pharmthera.2016.02.007" target="_blank" >http://dx.doi.org/10.1016/j.pharmthera.2016.02.007</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.pharmthera.2016.02.007" target="_blank" >10.1016/j.pharmthera.2016.02.007</a>

Result language

angličtina

Original language name

Cancer TARGETases: DSB repair as a pharmacological target

Original language description

Cancer is a disease attributed to the accumulation of DNA damages due to incapacitation of DNA repair pathways resulting in genomic instability and a mutator phenotype. Among the DNA lesions, double stranded breaks (DSBs) are the most toxic forms of DNA damage which may arise as a result of extrinsic DNA damaging agents or intrinsic replication stress in fast proliferating cancer cells. Accurate repair of DSBs is therefore paramount to the cell survival, and several classes of proteins such as kinases, nucleases, helicases or core recombinational proteins have pre-defined jobs in precise execution of DSB repair pathways. On one hand, the proper functioning of these proteins ensures maintenance of genomic stability in normal cells, and on the other hand results in resistance to various drugs employed in cancer therapy and therefore presents a suitable opportunity for therapeutic targeting. Higher relapse and resistance in cancer patients due to non-specific, cytotoxic therapies is an alarming situation and it is becoming more evident to employ personalized treatment based on the genetic landscape of the cancer cells. For the success of personalized treatment, it is of immense importance to identify more suitable targetable proteins in DSB repair pathways and also to explore new synthetic lethal interactions with these pathways. Here we review the various alternative approaches to target the various protein classes termed as cancer TARGETases in DSB repair pathway to obtain more beneficial and selective therapy.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FR - Pharmacology and apothecary chemistry

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Pharmacology &amp; Therapeutics

ISSN

0163-7258

e-ISSN

—

Volume of the periodical

161

Issue of the periodical within the volume

MAY

Country of publishing house

GB - UNITED KINGDOM

Number of pages

20

Pages from-to

111-131

UT code for WoS article

000375886600009

EID of the result in the Scopus database

—